Carogen Corp

Hamden, CT

UEI
JNMNVKEUU2Y3
CAGE
6TGS8
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Black American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
295 Washington Ave, Hamden, CT 06518, USA
Website
carogencorp.com
Founded
2012
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

About the company

Carogen Corp is a biopharmaceutical company based in Hamden, Connecticut, registered as a Minority Owned Business and Self Certified Small Disadvantaged Business. The company specializes in developing innovative vaccine platforms and immunotherapies, with a particular focus on treating chronic viral infections. Holding an exclusive license with Yale University for a replicating viral vector system, Carogen Corp has positioned itself as an emerging research-driven organization leveraging advanced nucleic acid delivery systems and immunomodulatory approaches to develop novel medical treatments.

Through federal grant awards, Carogen Corp has consistently secured funding from multiple federal agencies to advance research in viral disease treatment, particularly hepatitis B and influenza. The company has received significant project grants from the Defense Health Agency, Department of the Army Medical Command, and the National Institute of Allergy and Infectious Diseases, totaling over $6.1 million in recent awards. These grants have supported complex research initiatives, including developing a therapeutic vaccine (CARG-201) for chronic hepatitis B, exploring combination immunotherapies with checkpoint inhibition techniques, and creating self-amplifying RNA replicon-based vaccine platforms. The research spans multiple phases, with grant periods ranging from one to three years, demonstrating the company's commitment to advancing medical research through innovative therapeutic approaches targeting chronic viral infections and developing potential breakthrough treatment methodologies.

Quick answers

Is Carogen Corp registered in SAM.gov?

Yes. Carogen Corp's SAM.gov registration is active through August 4, 2027.

What is Carogen Corp's CAGE code?

Carogen Corp's CAGE code is 6TGS8, and its Unique Entity ID (UEI) is JNMNVKEUU2Y3.

What is Carogen Corp's most recent federal award?

Carogen Corp's most recent federal grant award is Testing the safety and efficacy of carg-201, an RNA replicon-based therapeutic vaccine for the treatment of chronic… (HT94252410951), from Defense Health Agency, on September 1, 2024.

On GovTribe

See Carogen Corp's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe